OnKure Therapeutics reported Q1 2026 results highlighting the nomination of two next-generation PI3Kα pan-mutant selective inhibitors, OKI-355 for vascular anomalies and OKI-345 for breast cancer. The company secured $150 million in private placement funding to support clinical development planned for 2027, with $192 million cash on hand expected to fund operations through 2029. OnKure is focusing on these inhibitors to provide targeted therapies with fewer toxicities and plans to submit IND applications to the FDA in the first half of 2027. The company also announced it will not independently pursue further development of OKI-219, another PI3Kα inhibitor, shifting focus to the new candidates.
Alliance Resource Partners reported Q2 revenue of $551.6 million, slightly below estimates, due to lower coal prices despite higher sales volumes. The company saw a 33.9% rise in net income to $79.6 million, supported by strong oil and gas royalties....
Welltower is set to report strong Q2 revenue growth of about $3.43 billion, a 34.5% increase year-over-year, reflecting robust demand in healthcare real estate. Earnings per share estimates vary widely, from $0.64 to $1.55, indicating uncertainty in ...
Christian Dior reported strong first-half 2026 results with €38.6 billion in sales and an operating profit of €8.7 billion, maintaining a high operating margin of 22.5%. The group saw a 3% organic sales growth in Q2, driven by strong performances in ...
Grabar Law Office is investigating potential shareholder claims against four companies—Cogent Communications, EquipmentShare.com, Photronics, and PROCEPT BioRobotics—alleging breaches of fiduciary duties and misleading disclosures. These investigatio...
PFK Canada has introduced Kwench, a new beverage brand offering nine specialty drinks in four categories: Krunch Shakes, Sparkling Lemonades, Pearl Tea Refreshments, and Iced Lattes. This marks PFK's first major expansion beyond its core food offerin...
